Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.44 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18486174 | 0.72 | SLC6A3 (0.48) | EHMT2EHMT1HRH3LTA4HDRD2 | |
| SCHEMBL6034080 | 0.72 | HRH3 (0.47) | HRH3TDP1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL2143951 | 0.71 | HRH3 (0.46) | EHMT2EHMT1HRH3TDP1L3MBTL1 | |
| SCHEMBL28900212 | 0.71 | SIGMAR1 (0.51) | HRH3LTA4HSIGMAR1DRD2SLC6A4 | |
| SCHEMBL4793724 | 0.69 | HRH3 (0.79) | HRH3TDP1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL7023474 | 0.69 | NOS2 (0.44) | CYP3A4 | |
| SCHEMBL31352350 | 0.68 | HRH3 (0.50) | HRH3CYP3A4SIGMAR1SLC6A4SLC6A3 | |
| SCHEMBL14138587 | 0.68 | ESR1 (0.43) | HRH3 | |
| SCHEMBL2322996 | 0.68 | HRH3 (0.47) | HRH3TDP1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL4090365 | 0.66 | HRH3 (0.49) | HRH3CYP1A2CYP3A4LTA4HSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538115-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-05-26 | — | — | US | disclosed |
| EP-1487821-B1 | BENZODIAZEPINE-SUBSTITUTED PIPERIDINES FOR UTILIZATION IN THE TREATMENT OF CARDIOVASCULAR DISEASES | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-03-21 | — | — | EP | disclosed |
| US-7026312-B2 | Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-04-11 | — | — | US | disclosed |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-09-29 | — | — | US | disclosed |
| EP-1487821-A1 | BENZODIAZEPINE-SUBSTITUTED PIPERIDINES FOR UTILIZATION IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-12-22 | — | — | EP | disclosed |
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2003-12-25 | — | — | US | disclosed |
| WO-2003076432-A1 | BENZODIAZEPINE-SUBSTITUTED PIPERIDINES FOR UTILIZATION IN THE TREATMENT OF CARDIOVASCULAR DISEASES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236282-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX5, CALCRL, ADRA1D | EHMT2 4839/4885EHMT1 4624/4885HRH3 259/4885 |
| US-20050215546-A1 | Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof | P2RX3, P2RX5, P2RX2 | EHMT2 4755/4885EHMT1 4563/4885HRH3 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.